Loading... Please wait...
Sort by:

 

FirstView NPS+

An expanded view of brand loyalty among doctors

Actionable metrics to help you make better brand decisions

 

Net Promoter Score (NPS) is an easy way to measure brand health, but it doesn’t tell you how to improve it. NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty

 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

  • NPS+ Multiple Myeloma (EU5) 2017
    Learn More NPS+ Multiple Myeloma (EU5) 2017
    How does your myeloma brand stack up against the competition? There are various options available to  EU5 oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving...
  • NPS+ Multiple Myeloma (US) 2017
    Learn More NPS+ Multiple Myeloma (US) 2017
    How does your myeloma brand stack up against the competition? There are various options available to US oncologists and haematologists to treat multiple myeloma. Clearly some of these options are achieving greater...
  • NPS+ Chronic Lymphocytic Leukaemia (CLL) (EU5) 2017
    Learn More NPS+ Chronic Lymphocytic Leukaemia (CLL) (EU5) 2017
    Why are some EU5 CLL brands standing out more than others? There are various options available to EU5 oncologists and haematologists to treat chronic lymphocytic leukaemia (CLL). Clearly some of these options are...
  • NPS+ Chronic Lymphocytic Leukaemia (CLL) (US) 2017
    Learn More NPS+ Chronic Lymphocytic Leukaemia (CLL) (US) 2017
    Why are some US CLL brands standing out more than others? There are various options available to US oncologists and haematologists to treat chronic lymphocytic leukaemia (CLL). Clearly some of these options are...
  • NPS+ Type 2 Diabetes Mellitus (EU5) 2017
    Learn More NPS+ Type 2 Diabetes Mellitus (EU5) 2017
    Why are some EU5 diabetes brands standing out more than others? There are various options available to European diabetologists and primary care physicians to treat Type 2 Diabetes Mellitus (T2DM). Clearly some of these...
  • NPS+ Type 2 Diabetes Mellitus (US) 2017
    Learn More NPS+ Type 2 Diabetes Mellitus (US) 2017
    Why are some US diabetes brands standing out more than others? There are various options available to US diabetologists and primary care physicians to treat Type 2 Diabetes Mellitus (T2DM). Clearly some of these...
  • NPS+ Rheumatoid Arthritis (US) 2017
    Learn More NPS+ Rheumatoid Arthritis (US) 2017
    How is brand health being impacted by new RA market entrants? The battle is on. Anti-TNF Biosimilars for rheumatoid arthritis (RA) have arrived in the US and we can now start to see the first changes in perception...
  • NPS+ Rheumatoid Arthritis (EU5) 2017
    Learn More NPS+ Rheumatoid Arthritis (EU5) 2017
    How is brand health being impacted by new RA market entrants? The battle is on. Anti-TNF Biosimilars for rheumatoid arthritis (RA) are making their mark across Europe and we can now start to see a shift in perception...
  • NPS+ Haemophilia A (EU5) 2017
    Learn More NPS+ Haemophilia A (EU5) 2017
    Doctors unhappy with available brands despite perceived efficacy Doctors in the EU5 countries say Haemophilia A drugs are safe and effective, but that doesn’t mean they’re happy with available brands. Nearly...
  • NPS+ Haemophilia A (US) 2017
    Learn More NPS+ Haemophilia A (US) 2017
    Major brands are stuck in a rut with US doctors Haemophilia A drugs seem to be stuck in a rut with US doctors. The majority of haematologists surveyed for this report say they’re satisfied with available brands,...
  • NPS+ Haemophilia B (EU5) 2017
    Learn More NPS+ Haemophilia B (EU5) 2017
    Does your brand messaging need an overhaul? Despite some positive feedback from haematologists in the EU5 countries, only one of the 6 Haemophilia B treatments we surveyed managed to eke out a positive satisfaction...
  • NPS+ Haemophilia B (US) 2017
    Learn More NPS+ Haemophilia B (US) 2017
    Major brands eke out a win but fail to wow doctors US haematologists had good things to say about the 6 Haemophilia B treatments we surveyed, but barely positive satisfaction ratings and low brand loyalty scores mean...
  •  NPS+ Non Small Cell Lung Cancer (EU5) 2017
    Learn More NPS+ Non Small Cell Lung Cancer (EU5) 2017
    Why are some European NSCLC  brands promoted more than others?    There are various options available to European medical oncologists to treat non-small cell lung carcinoma (NSCLC). Clearly some brands...
  • NPS+ Non Small Cell Lung Cancer (US) 2017
    Learn More NPS+ Non Small Cell Lung Cancer (US) 2017
    Which two US NSCLC brands are streets ahead of the competition?  There are various options available to US medical oncologists to treat non-small cell lung cancer (NSCLC). Clearly some of these options are...
  • NPS+ Growth Hormone Deficiency (EU5) 2017
    Learn More NPS+ Growth Hormone Deficiency (EU5) 2017
    Why are some European GHD brands promoted more by doctors than others?   There are various options available to European endocrinologists to treat growth hormone deficiency (GHD), including biosimilars...
  • NPS+ Growth Hormone Deficiency (US) 2017
    Learn More NPS+ Growth Hormone Deficiency (US) 2017
    Why are some US GHD brands standing out more than others?  There are various options available to US endocrinologists to treat growth hormone deficiency (GHD). Clearly some of these options are achieving greater...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved